Backbone vector plasmid of shRNA expressing lentivirus construct by Gateway(R) cloning with TetR-2A-Venus marker driven by EF-1 alpha promoter.
![]() Drawn by SnapGene® software |
|
| Clone info. | Backbone vector plasmid of shRNA expressing lentivirus construct by Gateway(R) cloning with TetR-2A-Venus marker driven by EF-1 alpha promoter. |
|---|---|
| Comment | pENTR4-H1tetOx1 (RDB07916) is used for construction of tetracyclin inducible shRNA expression vector. pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) are popular choices for lentivirus packaging. |
| Selectable markers | Ampicillin, Chloramphenicol, ccdB (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector. |
| Growth remarks | Use DB3.1, ccdB Survival or equivalent to amplify this clone. 30℃ is fine. |
| Depositor|Developer | Miyoshi, Hiroyuki | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Ordering instruction.[link] |
|---|---|
| Terms and conditions for distribution | The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product. |
| Remarks | Remember that you will be working with samples containing infectious virus. Use Survival2 (Invitrogen) or equivalent to amplify this clone. Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。 付加的使用条件: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。 |
| 備考 | このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 このクローンの増殖にはSurvival2 (Invitrogen)あるいは同等の宿主を使用してください。 ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。 |
| Catalog # | Resource name | Shipping form | Fee |
|---|---|---|---|
| RDB08020 | CS-RfA-ETV | Please contact us. |
Materials & Methods section:
| The CS-RfA-ETV was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB08020). |
Reference section:
Further references such as user reports and related articles (go to bottom)
Original, user report and related articles
| reference | Noura, M., Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia. 29 June 2023, PREPRINT (Version 1) available at Research Square https://doi.org/10.21203/rs.3.rs-3069900/v1 [Article] |
|---|---|
| user_report | Masuda, T., Cancer Accumulation and Anticancer Activity of CROX (Cluster Regulation of RUNX) PIP in HER2-Positive Gastric Cancer Evaluated by Chicken Egg Cancer Model. Cancer Med. 14 (7): e70845 (2025). PMID 40171874. [PubMed] [Article] [RRC of NBRP] |
| user_report | Noura, M., Induction of T-Cell Differentiation by KLF4 in T-Cell Acute Lymphoblastic Leukemia Cells Harboring Activating Mutation in NOTCH3. FASEB J. 39 (10): e70613 (2025). PMID 40354086. [PubMed] [Article] [RRC of NBRP] |
| user_report | Watanabe, K., Inhibition of the galactosyltransferase C1GALT1 reduces osteosarcoma cell proliferation by interfering with ERK signaling and cell cycle progression. Cancer Gene Ther. 31 (7): 1049-1059 (2024). PMID 38622340. [PubMed] [Article] [RRC of NBRP] |
| user_report | Matsui, Y., Chlorambucil-conjugated PI-polyamides (Chb-M'), a transcription inhibitor of RUNX family, has an anti-tumor activity against SHH-type medulloblastoma with p53 mutation. Biochem. Biophys. Res. Commun. 620: 150-157 (2022). PMID 35792512. [PubMed] [Article] [RRC of NBRP] |
| user_report | Hattori, E.Y., A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice. Commun. Biol. 5 (1): 939 (2022). PMID 36085167. [PubMed] [Article] [RRC of NBRP] |
| user_report | Noura, M., Pivotal role of DPYSL2A in KLF4-mediated monocytic differentiation of acute myeloid leukemia cells. Sci. Rep. 10 (1): 20245 (2020). PMID 33219287. [PubMed] [Article] [RRC of NBRP] |
| user_report | Morita, K., RUNX transcription factors potentially control E-selectin expression in the bone marrow vascular niche in mice. Blood Adv. 2 (5): 509-515 (2018). PMID 29500219. [PubMed] [Article] [RRC of NBRP] |
| user_report | Mitsuda, Y., RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci. Rep. 8 (1): 6423 (2018). PMID 29686309. [PubMed] [Article] [RRC of NBRP] |
| user_report | Morita, K., Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127 (7): 2815-2828 (2017). PMID 28530640. [PubMed] [Article] [RRC of NBRP] |
| user_report | Morita, K., Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Sci. Rep. 7 (1): 16604 (2017). PMID 29192243. [PubMed] [Article] [RRC of NBRP] |
| user_report | Morita, K., Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 1: 1440-1451 (2017). PMID 29296785. [PubMed] [Article] [RRC of NBRP] |
Featured content